Is Hepatocellular Carcinoma in Fatty Liver Different to Non-Fatty Liver?

Background: Non-alcoholic fatty liver disease (NAFLD) has become the most prevalent liver disease in Australia and is recognised to play a role in the development of hepatocellular carcinoma (HCC). There are no clear guidelines regarding screening for HCC in NAFLD. The aim of this retrospective stud...

Full description

Saved in:
Bibliographic Details
Published in:Nutrients 2022-09, Vol.14 (18), p.3875
Main Authors: Nguyen, Xuan-vinh Kevin, Zhang, Jason, Chin, Ken Lee, Bloom, Stephen, Nicoll, Amanda J
Format: Article
Language:English
Subjects:
Alcohol
Body mass index
Cancer therapies
Chi-square test
chronic liver disease
cirrhosis
Complications and side effects
Development and progression
Diabetes
Ethnicity
Etiology
Fatty liver
fatty liver disease
Hepatitis B
Hepatitis C
Hepatocellular carcinoma
Hepatoma
Histology
Hypertension
Liver
Liver cancer
Liver diseases
Medical records
Medical screening
Metabolic syndrome
non-alcoholic fatty liver disease
Patients
Population
Prognosis
Risk factors
Signs and symptoms
Surveillance
Survival
Survival analysis
Type 2 diabetes
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background: Non-alcoholic fatty liver disease (NAFLD) has become the most prevalent liver disease in Australia and is recognised to play a role in the development of hepatocellular carcinoma (HCC). There are no clear guidelines regarding screening for HCC in NAFLD. The aim of this retrospective study was to compare the characteristics and survival rates of NAFLD-HCC to patients with non-NAFLD-HCC to help guide future research in this area. Methods: A total of 152 HCC patients with either NAFLD (n = 36) or non-NAFLD (n = 116) were retrospectively analysed from the HCC database and medical records. Chi-square and independent t-test were used to compare baseline characteristics and Kaplan–Meier curves and Cox models were used for survival analysis. Results: Patients with NAFLD-HCC were more likely to be diagnosed due to symptoms rather than through screening, and at an older age, compared with non-NAFLD HCC. The median survival rates were lower in NAFLD-HCC (17.2 months) than in those with non-NAFLD-HCC (23.5 months). Conclusion: There is a rise in the number of HCC cases in patients with NAFLD, and this has significant implications for hepatologists as they are presented with more advanced diseases and have poorer outcomes. Future studies on HCC will need to identify this group earlier in order to have an impact on the HCC survival rate.
ISSN:2072-6643
2072-6643
DOI:10.3390/nu14183875